Vorsetuzumab mafodotin
Vorsetuzumab Mafodotin
Vorsetuzumab Mafodotin (pronunciation: vor-set-uh-zoo-mab maf-oh-doe-tin) is a monoclonal antibody-drug conjugate designed for the treatment of cancer.
Etymology
The name Vorsetuzumab Mafodotin is derived from the components of the drug. 'Vorsetuzumab' is the monoclonal antibody that targets the CD70 antigen, and 'Mafodotin' is the cytotoxic drug that is attached to the antibody.
Mechanism of Action
Vorsetuzumab Mafodotin works by binding to the CD70 antigen on the surface of cancer cells. The drug is then internalized by the cell, where the cytotoxic drug is released to kill the cell.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- CD70 Antigen: A protein found on the surface of some types of cancer cells.
- Cytotoxic Drug: A medication that kills cells, especially cancer cells.
Side Effects
Common side effects of Vorsetuzumab Mafodotin include fatigue, nausea, and decreased appetite. More serious side effects can include liver damage and severe allergic reactions.
See Also
- Antibody-Drug Conjugate: A type of drug that combines an antibody with a chemotherapy drug.
- Cancer Treatment: Methods of treating cancer, including surgery, radiation, and chemotherapy.
External links
- Medical encyclopedia article on Vorsetuzumab mafodotin
- Wikipedia's article - Vorsetuzumab mafodotin
This MedicineGPT article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski